| scholarly article | Q13442814 |
| P50 | author | David A. Isenberg | Q42326409 |
| P2093 | author name string | Elizabeth Allen | |
| Anisur Rahman | |||
| Sharon A Chambers | |||
| P2860 | cites work | Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus | Q33329033 |
| Lupus erythematosus in the 1980s: a survey of 570 patients | Q33384712 | ||
| Can morbidity and mortality of SLE be improved? | Q34664126 | ||
| Revisiting the issue of malignancy risk in systemic lupus erythematosus | Q36319625 | ||
| Socioeconomic status in systemic lupus erythematosus | Q36676990 | ||
| Mortality in systemic lupus erythematosus | Q38467155 | ||
| Current causes of death in systemic lupus erythematosus in Europe, 2000--2004: relation to disease activity and damage accrual. | Q44699349 | ||
| Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage | Q45099953 | ||
| Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage | Q47684491 | ||
| Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. | Q50563149 | ||
| P433 | issue | 6 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| patient | Q181600 | ||
| lupus erythematosus | Q188297 | ||
| P304 | page(s) | 673-675 | |
| P577 | publication date | 2009-04-09 | |
| P1433 | published in | Rheumatology | Q7320492 |
| P1476 | title | Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. | |
| P478 | volume | 48 |
| Q47967726 | Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period |
| Q41680597 | Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus |
| Q48182257 | Antiphospholipid antibodies, steroid dose, arterial hypertension, relapses, and late-onset predict organ damage in a population of Colombian patients with systemic lupus erythematosus. |
| Q53079370 | Assessment of clinical manifestations, disease activity and organ damage in 996 Korean patients with systemic lupus erythematosus: comparison with other Asian populations. |
| Q35146106 | Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus |
| Q35893859 | Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Population-Based Study, 1996-2011. |
| Q44615394 | Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel |
| Q33937936 | Cancer complicating systemic lupus erythematosus--a dichotomy emerging from a nested case-control study |
| Q58847539 | Causes and predictors of death in Brazilian lupus patients |
| Q51299667 | Causes and predictors of mortality in hospitalized lupus patient in Sarawak General Hospital, Malaysia. |
| Q90391852 | Changing trends in mortality in systemic lupus erythematosus? An analysis of SLE inpatient mortality at University Hospital Coventry and Warwickshire NHS Trust from 2007 to 2016 |
| Q56966244 | Characterization of damage in Portuguese lupus patients: analysis of a national lupus registry |
| Q38223293 | Childhood onset systemic lupus erythematosus: how is it different from adult SLE? |
| Q37127464 | Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus |
| Q39151466 | Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus |
| Q38650606 | Concerns of patients with systemic lupus erythematosus and adherence to therapy - a qualitative study |
| Q53102157 | Damage in lupus patients--what have we learned so far? |
| Q36192962 | Damage in the Multiethnic Malaysian Systemic Lupus Erythematosus (SLE) Cohort: Comparison with Other Cohorts Worldwide |
| Q35803646 | Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). |
| Q38162490 | Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus |
| Q33431990 | Differences in disease phenotype and severity in SLE across age groups |
| Q54263409 | Disease characteristics and causes of early and late death in a group of Croatian patients with systemic lupus erythematosus deceased over a 10-year period. |
| Q37228138 | Disease features and outcomes in United States lupus patients of Hispanic origin and their Mestizo counterparts in Latin America: a commentary |
| Q45081541 | Early lupus erythematosus |
| Q41260389 | Endothelial dysfunction in systemic lupus erythematosus - a case-control study and an updated meta-analysis and meta-regression |
| Q53839415 | Epidemiology of systemic lupus erythematosus. |
| Q35657280 | Evaluation of damage index and its association with risk factors in patients with systemic lupus erythematosus. |
| Q46301201 | Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort |
| Q28608340 | Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort |
| Q64038871 | Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: effect of conditioning regimen on outcome |
| Q38066385 | Global trends, potential mechanisms and early detection of organ damage in SLE. |
| Q37978291 | Glucocorticoid use and abuse in SLE. |
| Q35907785 | Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis |
| Q35162593 | IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study |
| Q34592686 | Incidence and prevalence of major central nervous system involvement in systemic lupus erythematosus: a 3-year prospective study of 370 patients |
| Q37464030 | Independent association of glucocorticoids with damage accrual in SLE. |
| Q43041710 | Influence of predialysis comorbidity and damage accrual on mortality in lupus patients treated with peritoneal dialysis |
| Q41908236 | Interleukin-6 receptor alpha blockade improves skin lesions in a murine model of systemic lupus erythematosus. |
| Q39053147 | It hasn't gone away: the problem of glucocorticoid use in lupus remains. |
| Q57167326 | Long-term clinical outcomes in a cohort of adults with childhood-onset Systemic Lupus Erythematosus |
| Q47199208 | Long-term mortality and morbidity of patients with systemic lupus erythematosus: a single-center cohort study in China. |
| Q33801123 | Longitudinal validation of the Brief Index of Lupus Damage |
| Q43474417 | Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort |
| Q33730536 | Management of cardiovascular complications in systemic lupus erythematosus |
| Q39480930 | Medical costs incurred by organ damage caused by active disease, comorbidities and side effect of treatments in systemic lupus erythematosus patients: a Taiwan nationwide population-based study. |
| Q90014036 | Metabolomics approach reveals urine biomarkers and pathways associated with the pathogenesis of lupus nephritis |
| Q46665204 | Mortality and causes of death among incident cases of systemic lupus erythematosus in Finland 2000-2008. |
| Q44800972 | Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). |
| Q40126330 | Mortality in systemic lupus erythematosus in the United Kingdom 1999-2012. |
| Q39231524 | Neuro-ophthalmologic manifestations in systemic lupus erythematosus |
| Q48663436 | Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years |
| Q35600608 | Organ damage in high-risk patients with systemic and incomplete lupus syndromes |
| Q33723511 | Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? |
| Q38771936 | Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus |
| Q33555419 | Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort |
| Q37777642 | Prevalence and burden of pediatric-onset systemic lupus erythematosus |
| Q38175493 | Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies. |
| Q43581917 | Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus |
| Q37350506 | Relationship Between Systemic Lupus Erythematosus Disease Activity Index Scores and Subclinical Cardiac Problems |
| Q40831626 | Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry |
| Q33766242 | Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study |
| Q42281246 | Serum protein pattern associated with organ damage and lupus nephritis in systemic lupus erythematosus revealed by PEA immunoassay |
| Q47687376 | Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register |
| Q50848358 | Systemic lupus erythematosus. |
| Q51135582 | The Sarawak lupus cohort: clinical features and disease patterns of 633 SLE patients in a single tertiary centre from East Malaysia. |
| Q46216656 | The causes of death in Korean patients with systemic lupus erythematosus over 11 years |
| Q40047382 | The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort. |
| Q28072610 | The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus |
| Q38784456 | The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. |
| Q91803860 | The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts |
| Q30756915 | The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. |
| Q37627356 | The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness |
| Q37879597 | To what extent can preventive treatments prevent damage from systemic lupus erythematosus? |
| Q46054284 | Towards treating lupus nephritis without oral steroids: a dream-come-true? |
| Q38205079 | Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. |
| Q52654857 | Update on Antiphospholipid Syndrome: Ten Topics in 2017. |
| Q37690103 | Update on differences between childhood-onset and adult-onset systemic lupus erythematosus |
| Q51030902 | Urinary CXCL-10/IP-10 and MCP-1 as markers to assess activity of lupus nephritis. |
| Q42947364 | Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis |
| Q44476349 | Validation and evaluation of the German Brief Index of Lupus Damage (BILD)--a self-reported instrument to record damage in systemic lupus erythematosus. |
| Q33631028 | Validity of a self-administered version of the brief index of lupus damage in a predominantly African American systemic lupus erythematosus cohort |
Search more.